ALNYLAM PHARMACEUTICALS, INC. Net Change in Cash
ALNYLAM PHARMACEUTICALS, INC. (ALNY) reported Net Change in Cash of $50.67 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Cash Flow › Change in Cash
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect · last filed 2026-07-30
- ALNYLAM PHARMACEUTICALS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2025-03-31 was $53.60M.
- ALNYLAM PHARMACEUTICALS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2024-03-31 was -$130.16M.
- ALNYLAM PHARMACEUTICALS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2023-03-31 was -$194.15M.
- ALNYLAM PHARMACEUTICALS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2022-03-31 was -$285.89M.
- ALNYLAM PHARMACEUTICALS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2025 was $690.15M, a 348.83% increase from fiscal 2024.
- ALNYLAM PHARMACEUTICALS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2024 was $153.77M.
- ALNYLAM PHARMACEUTICALS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2023 was -$53.67M, a 215.66% decline from fiscal 2022.
- ALNYLAM PHARMACEUTICALS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2022 was $46.40M, a 85.64% decline from fiscal 2021.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 3 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 6 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 9 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 12 month |
|---|---|---|---|---|
| 2026-06-30 | $50.67M 10-Q · filed 2026-07-30 | |||
| 2025-12-31 | $690.15M 10-K · filed 2026-02-12 | |||
| 2025-09-30 | $524.15M 10-Q · filed 2025-10-30 | |||
| 2025-06-30 | $147.21M 10-Q · filed 2026-07-30 | |||
| 2025-03-31 | $53.60M 10-Q · filed 2025-05-01 | |||
| 2024-12-31 | $153.77M 10-K · filed 2026-02-12 | |||
| 2024-09-30 | $287.61M 10-Q · filed 2025-10-30 | |||
| 2024-06-30 | $156.31M 10-Q · filed 2025-07-31 | |||
| 2024-03-31 | -$130.16M 10-Q · filed 2025-05-01 | |||
| 2023-12-31 | -$53.67M 10-K · filed 2026-02-12 | |||
| 2023-09-30 | $166.65M 10-Q · filed 2024-10-31 | |||
| 2023-06-30 | -$208.58M 10-Q · filed 2024-08-01 | |||
| 2023-03-31 | -$194.15M 10-Q · filed 2024-05-02 | |||
| 2022-12-31 | $46.40M 10-K · filed 2025-02-13 | |||
| 2022-09-30 | $253.24M 10-Q · filed 2023-11-02 | |||
| 2022-06-30 | -$244.42M 10-Q · filed 2023-08-03 | |||
| 2022-03-31 | -$285.89M 10-Q · filed 2023-05-04 | |||
| 2021-12-31 | $323.11M 10-K · filed 2024-02-15 | |||
| 2021-09-30 | $597.41M 10-Q · filed 2022-10-27 | |||
| 2021-06-30 | $249.02M 10-Q · filed 2022-07-28 | |||
| 2021-03-31 | -$117.04M 10-Q · filed 2022-04-28 | |||
| 2020-12-31 | -$50.58M 10-K · filed 2023-02-23 | |||
| 2020-09-30 | -$50.47M 10-Q · filed 2021-10-28 | |||
| 2020-06-30 | $33.65M 10-Q · filed 2021-08-03 | |||
| 2020-03-31 | -$79.23M 10-Q · filed 2021-04-29 | |||
| 2019-12-31 | $127.00M 10-K · filed 2022-02-10 | |||
| 2019-09-30 | $503.12M 10-Q · filed 2020-11-05 | |||
| 2019-06-30 | $716.97M 10-Q · filed 2020-08-06 | |||
| 2019-03-31 | $305.07M 10-Q · filed 2020-05-06 | |||
| 2018-12-31 | -$224.20M 10-K · filed 2021-02-11 | |||
| 2018-09-30 | -$328.09M 10-Q · filed 2019-10-31 | |||
| 2018-06-30 | -$283.44M 10-Q · filed 2019-08-06 | |||
| 2018-03-31 | -$248.96M 10-Q · filed 2019-05-02 | |||
| 2017-12-31 | $451.74M 10-K · filed 2020-02-13 | |||
| 2017-09-30 | $8.43M 10-Q · filed 2018-11-07 | |||
| 2017-06-30 | $215.05M 10-Q · filed 2018-08-02 | |||
| 2016-12-31 | $12.72M 10-K · filed 2019-02-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |